Adjuvant Systemic Therapy Trials in Early Breast Cancer

  • Data from the Early Breast Cancer Trialists’ Collaborative Group meta-analysis of adjuvant systemic therapy trials begun in or before 1995 show:A 30% relative reduction in breast cancer-related mortality associated with adjuvant hormonal therapy and with adjuvant chemotherapy. Reduced rates of:Ipsilateral local recurrenceContralateral cancers
      • Distant metastasesThese suggests there is eradication of occult residual disease in many patients.
    • The absolute survival benefit of adjuvant therapy is greater in node-positive than in node-negative patients.
    • The absolute survival benefit of chemotherapy is greater for younger (<50 years of age) than for older women (50 to 69 years of age).

img_0832-2img_0833-2img_0834-2img_0835-2img_0836-2img_0837-2

Rodrigo Arrangoiz MS, MD, FACS a surgical oncologist and is a member of Sociedad Quirúrgica S.C at the America British Cowdray Medical Center in Mexico City:

  • He is an expert in the management of breast cancer.

    • If you have any questions about the screening for breast cancer please fill free to contact Dr. Arrangoiz.

Training:

• General surgery:

• Michigan State University:

• 2004 al 2010

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• Fox Chase Cancer Center (Filadelfia):

• 2010 al 2012

• Masters in Science (Clinical research for health professionals):

• Drexel University (Filadelfia):

• 2010 al 2012

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• IFHNOS / Memorial Sloan Kettering Cancer Center:

• 2014 al 2016

#Arrangoiz

#Surgeon

#Cirujano

#SurgicalOncologist

#CirujanoOncologo

#BreastSurgeon

#CirujanodeMama

#CancerSurgeon

#CirujanodeCancer

http://www.sociedadquirurigca.com

Leave a comment